截至9时25分，利德曼涨停，涨幅19.93%，最新价7.04元，成交额0.36亿元，封单金额4.18亿元。公司7 月30日晚公告，拟以现金收购北京先声祥瑞生物制品股份有限公司不超过70%股份，交易预计构成重大 资产重组。目标公司主营结核诊断试剂及疫苗产品，2025年一季度利德曼营收7891万元，净利润亏损 125万元。 风险提示：收购事项尚处筹划阶段，存在审批未通过风险，二级市场波动需谨慎。 ...

Group 1 - The stock price of Baipusais experienced volatility on July 30, opening at 57.01 yuan, dropping to a low of 54.72 yuan, and closing at 55.41 yuan, a decrease of 2.21% from the previous trading day [1] - During the trading session, there was a rapid rebound, with the stock price increasing over 2% within 5 minutes at 9:37 AM, reaching 57.27 yuan [1] - On July 30, the net outflow of main funds was 1.583 million yuan, accounting for 0.02% of the circulating market value, with a trading volume of 41,500 lots and a transaction amount of 233 million yuan [1] Group 2 - Baipusais is a company focused on the biopharmaceutical sector, primarily engaged in the research, development, production, and sales of recombinant proteins and other biological products [1] - The company's products are mainly applied in drug research and development, as well as vaccine production [1]

Group 1 - The core stock price of Bid Pharma on July 30 was 59.06 yuan, down by 2.42 yuan, representing a decline of 3.94% [1] - The trading volume on the same day was 100 million yuan, with a turnover rate of 3.84%, and the total market capitalization stood at 5.368 billion yuan [1] - Bid Pharma specializes in the biopharmaceutical sector, focusing on pharmaceutical research and development services, and operates within the bioproducts and CRO industry segments [1] Group 2 - The company will hold its fourth extraordinary general meeting of shareholders for 2025 on July 31 to discuss multiple proposals, including changes to its business scope, the cancellation of the supervisory board, and amendments to the company’s articles of association [1] - The meeting will take place at the conference room on the 6th floor of Building 3, No. 999 Xiangyin Road, Yangpu District, Shanghai [1] - On July 30, the net outflow of main funds was 15.3766 million yuan, accounting for 0.6% of the circulating market value [1]

Group 1 - The stock price of Jinkai Biotechnology is reported at 39.28 yuan as of July 30, 2025, reflecting a decline of 1.73% from the previous trading day [1] - The trading volume on the same day reached 263 million yuan, with a turnover rate of 11.73% [1] - Jinkai Biotechnology's main business includes bioproducts, weight loss drugs, and CRO services, and the company is part of the Liaoning sector with specialized and innovative qualifications [1] Group 2 - Shareholder Qilu Investment has reduced its holdings by a total of 4,477,700 shares between December 18, 2024, and July 28, 2025, accounting for 3.72% of the total share capital, bringing its ownership down to 4.99996% [1] - On July 30, 2025, the net outflow of main funds was 27.78 million yuan [1]

Group 1 - The company held its 30th meeting of the 5th Board of Directors on July 30, 2025, via telecommunication, with all 10 directors present, confirming compliance with legal and regulatory requirements [1] - The Board approved the signing of an amendment to the Exclusive Sublicense Agreement with Notitia Biotechnologies Company, granting the company exclusive rights to develop, manufacture, and commercialize core microbiome analysis, microbiome-targeted transplantation, and nutritional formula technologies in mainland China, Hong Kong, and Macau for non-patient populations [1][2] - The Board also approved the application for credit facilities from several banks, including China Construction Bank, China Merchants Bank, Agricultural Bank of China, and others, to support the company's and its subsidiaries' research, production, sales, and daily operational expenses [2][6] Group 2 - The approved credit facilities will include comprehensive credit, working capital loans, project loans, bank acceptance bills, and guarantees, all of which will be unsecured [3][4][5] - The financial department is authorized to determine financing methods, amounts, terms, and interest rates within the approved credit limits, with legal representatives signing relevant contracts and documents [6]

证券代码：300142 证券简称：沃森生物 公告编号：2025-037 云南沃森生物技术股份有限公司 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 云南沃森生物技术股份有限公司（以下简称"公司"）第五届监事会第二十一 次会议于 2025 年 7 月 30 日以通讯表决的方式召开，会议通知于 7 月 27 日以电子 邮件方式发出。本次会议应参会监事 3 人，实际参加会议监事 3 人。会议由监事 会主席丁世青女士主持。本次会议的召集、召开符合《公司法》及《公司章程》 的规定。 二、监事会会议审议情况 审议通过了《关于公司及子公司向银行申请授信额度的议案》 监事会同意公司及子公司玉溪沃森生物技术有限公司（以下简称"玉溪沃 森"）、玉溪泽润生物技术有限公司（以下简称"玉溪泽润"）根据业务发展及 日常运营需要，向中国建设银行股份有限公司玉溪市分行（以下简称"建设银行"）、 招商银行股份有限公司昆明分行（以下简称"招商银行"）、中国农业银行股份 有限公司玉溪分行（以下简称"农业银行"）、中国光大银行股份有限公司昆明 分行（以下简称"光大银行"）、 ...

Core Viewpoint - The document outlines the management system for the resignation of directors and senior management personnel at Shandong Weiming Biological Pharmaceutical Co., Ltd, aiming to ensure stability in corporate governance and protect the rights of the company and its shareholders [1]. Group 1: General Provisions - The management system is established in accordance with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [1]. - The system applies to directors and senior management personnel who leave due to term expiration, resignation, dismissal, retirement, or other reasons [1]. Group 2: Resignation Circumstances and Procedures - Directors can resign before their term expires by submitting a written resignation report, which becomes effective upon receipt by the company, and the company must disclose this within two trading days [2]. - If a director's resignation results in the board falling below the legal minimum number of members, the resigning director must continue to fulfill their duties until a new board is elected [2]. - The company must complete the election of a new director within sixty days if an independent director resigns or is dismissed [2]. Group 3: Responsibilities and Obligations of Resigning Directors and Senior Management - Resigning directors and senior management must hand over all relevant documents and assets to the board before leaving, and they must cooperate with the company in follow-up investigations regarding significant matters during their tenure [4]. - Any public commitments made by directors and senior management during their tenure must continue to be honored after resignation, and failure to fulfill these commitments may result in liability for damages [4][5]. - After leaving, directors and senior management are prohibited from using their former positions to interfere with the company's operations or harm the interests of the company and its shareholders [5]. Group 4: Accountability Mechanism - If the company discovers that a resigning director or senior management has failed to fulfill commitments or has violated their duties, the board will review the situation and determine specific accountability measures, which may include compensation for direct losses and expected benefits [6]. - Resigning individuals can appeal the accountability decisions to the company's audit committee within fifteen days of notification [6]. Group 5: Supplementary Provisions - Any matters not covered by this system will be executed according to relevant laws and regulations, and the board of directors is responsible for interpreting the system [7]. - The management system will take effect from the date of approval by the board and will be modified accordingly [7].

Core Points - The document outlines the work system for the Secretary of the Board of Directors of Shandong Weiming Biological Pharmaceutical Co., Ltd, aiming to enhance corporate governance and the role of the board secretary [1][2] - The board secretary is a senior management position responsible for communication with the Shenzhen Stock Exchange and managing shareholder and board meeting preparations [2][3] Section Summaries General Provisions - The board secretary is designated as the contact person for the company with the Shenzhen Stock Exchange and is responsible for various administrative tasks related to board and shareholder meetings [2][3] Qualifications - The board secretary must possess necessary financial, management, and legal knowledge, and must hold a qualification certificate recognized by the Shenzhen Stock Exchange [3] Responsibilities and Duties - The board secretary is responsible for managing information disclosure, coordinating investor relations, and ensuring compliance with relevant regulations [5][6] - The secretary must maintain confidentiality regarding undisclosed significant information and report any leaks to the exchange promptly [5][6] - The board secretary also oversees the management of the company's stock and related transactions [4][5] Appointment Procedures - The board secretary is nominated by the chairman and appointed by the board, with specific documentation required for the appointment [8][9] - In case of vacancy, the board must appoint an interim secretary and complete the hiring process within a specified timeframe [9] Legal Responsibilities - The board secretary shares liability for decisions that violate laws or regulations, but can be exempted if they can prove dissenting opinions were expressed [10][10]

General Principles - The document outlines the stamp management system of Shandong Weiming Biological Pharmaceutical Co., Ltd, aiming to standardize and streamline the management of stamps to protect the company's legal rights [1][2] - The system applies to the company, its subsidiaries, and departments regarding the management and use of various stamps [1] Types of Stamps - The types of stamps include company seals, legal representative seals, financial seals, contract seals, board seals, departmental seals, and electronic seals, all of which have legal validity [1][2] - Specific uses for each type of stamp are defined, such as the company seal for important documents and the legal representative seal for official certifications [2] Stamp Creation and Approval - The creation of stamps must follow legal procedures and be approved by designated authorities within the company [3][4] - Different stamps have specific approval processes, such as the board seal requiring approval from the board secretary and chairman [3][4] Stamp Custody - A separation of duties and decentralized custody system is established for stamp management, ensuring that stamp custodians do not personally approve their own usage [4] - Designated personnel are responsible for the custody of different types of stamps, with a requirement for proper documentation and reporting in case of loss or damage [4][5] Stamp Usage - A pre-approval and registration system is in place for stamp usage, requiring departments to submit requests that must be approved by authorized personnel [5][6] - Stamps should not be used on incomplete documents or blank forms, and any unauthorized use will be reported and addressed [6][7] Stamp Abolition and Destruction - Procedures for abolishing and destroying stamps are outlined, including the need for approval and proper documentation when stamps are no longer in use [7][8] - Stamps that are required for ongoing legal or business matters must be retained until those matters are resolved [8] Responsibilities - Unauthorized creation or use of stamps is strictly prohibited, with consequences for individuals who violate these rules [8][9] - Stamp custodians are responsible for the safe keeping of stamps and must report any loss or unauthorized use immediately [9]

General Principles - The financial management system of Shandong Weiming Biological Pharmaceutical Co., Ltd. aims to standardize accounting recognition, measurement, and reporting to ensure the quality of accounting information and improve economic efficiency while protecting shareholders' rights [1][2][3] Financial Management Structure and Personnel - The company has established a financial management organization under the leadership of the board of directors, with the general manager responsible for implementation [2][3] - A planning finance center is set up to handle financial management and accounting matters, staffed with qualified accounting personnel [2][3] - The company has the authority to appoint and dismiss financial heads of its subsidiaries, while other financial personnel are hired according to internal regulations [2][3] Accounting Policies and Estimates - The company adopts a calendar year as its accounting period, running from January 1 to December 31 [3][4] - The functional currency for accounting is determined based on the primary economic environment, with RMB used for companies established in mainland China [4][5] - The company uses the accrual basis of accounting and historical cost for measurement [4][5] Financial Asset Recognition and Measurement - Financial assets are classified at initial recognition into categories such as amortized cost, fair value through other comprehensive income, and fair value through profit or loss [5][6] - The company assesses credit risk and recognizes impairment losses based on expected credit losses [8] Inventory Accounting - Inventory is initially measured at cost and includes raw materials, finished goods, work in progress, and low-value consumables [9] - The company uses the weighted average method for inventory issuance and recognizes impairment when the cost exceeds the net realizable value [9] Long-term Equity Investment Accounting - The company uses the cost method for subsequent measurement of long-term equity investments in subsidiaries and adjusts for equity method in consolidated financial statements [10] Fixed Assets and Depreciation - Fixed assets are recorded at actual cost and depreciated using the average annual method based on asset categories [11][12] Intangible Assets Accounting - Intangible assets are initially measured at cost, including purchase price and related expenses, and are amortized over their useful lives [13][14] Revenue Recognition - Revenue is recognized when control of the goods is transferred to the customer, and specific criteria must be met [21] Tax Accounting - The company uses the balance sheet liability method for income tax accounting, recognizing deferred tax assets or liabilities based on differences between the book value and tax base of assets and liabilities [17] Financial Reporting - The company prepares financial reports including balance sheets, income statements, cash flow statements, and changes in equity statements, adhering to relevant accounting standards [23][24][25]